CD8A and neoplasm: This upregulation boosts CD8+ T cell infiltration and augments the effectiveness of anti‐PD‐L1 therapy, suggesting cediranib's potential to improve immunotherapy outcomes through modulation of tumour immunogenicity134 (Figure 6).